logo

CRIS

Curis
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 3
stock price surged significantly
consensus rating "Strong Buy"
EPS Below Expectations
Revenue Below Expectations
Revenue Keeps Dropping

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About CRIS

Curis, Inc.

A biotechnology company that developing innovative therapeutics for the treatment of cancer

Biological Technology
Invalid Date
08/01/2000
NASDAQ Stock Exchange
33
12-31
Common stock
128 Spring Street, Building C - Suite 500, Lexington, Massachusetts, 02421
--
Curis, Inc., was incorporated as a Delaware corporation in February 2000. The company is a biotechnology company focused on the development of emavusertib, an oral, small-molecule inhibitor of the interleukin -1 receptor-associated kinase.

Company Financials

EPS

CRIS has released its 2024 Q4 earnings. EPS was reported at -1.25, versus the expected -1.24, missing expectations. The chart below visualizes how CRIS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CRIS has released its 2024 Q4 earnings report, with revenue of 3.35M, reflecting a YoY change of 24.07%, and net profit of -9.62M, showing a YoY change of 17.88%. The Sankey diagram below clearly presents CRIS’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime